Anzeige
Mehr »
Freitag, 11.09.2026 - Börsentäglich über 12.000 News
Positiver Ausblick: "STRONG BUY" für NurExone Biologic!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P723 | ISIN: KYG674111011 | Ticker-Symbol: 5DG
Frankfurt
11.09.26 | 08:10
0,565 Euro
-1,74 % -0,010
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
OCUMENSION THERAPEUTICS Chart 1 Jahr
5-Tage-Chart
OCUMENSION THERAPEUTICS 5-Tage-Chart
RealtimeGeldBriefZeit
0,5650,62021:58
0,5650,62021:58

Aktuelle News zur OCUMENSION THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03:47OCUMENSION-B OT-301 New Drug Application for Lowering Intraocular Pressure Accepted2
01:00OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-301 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2
03.09.OCUMENSION-B Completes Patient Enrollment for Phase III Clinical Trial of OT-2111
02.09.OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-211-
01.09.OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF APPLICATION FOR DRUG REGISTRATION OF DOMESTICALLY PRODUCED DEXAMETHASONE INTRAOCULAR SUSPENSION-
31.08.OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-202-
OCUMENSION THERAPEUTICS Aktie jetzt für 0€ handeln
28.08.OCUMENSION-B (01477): CHANGE IN USE OF PROCEEDS1
28.08.OCUMENSION-B (01477): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026-
14.08.OCUMENSION-B (01477): DATE OF BOARD MEETING-
10.08.NICOX SA: Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension665Press Release Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension Ocumension has submitted the New Drug Application (NDA) to the Chinese National Medical Products Administration...
► Artikel lesen
02.07.OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-502 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION1
30.06.OCUMENSION-B (01477): RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY AND CHANGE IN AUTHORIZED REPRESENTATIVE1
30.06.OCUMENSION-B (01477): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION-
30.06.OCUMENSION-B (01477): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026 AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE ...-
08.06.OCUMENSION-B (01477): NOTICE OF ANNUAL GENERAL MEETING2
08.06.OCUMENSION-B (01477): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 30, 20261
08.06.OCUMENSION-B (01477): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED ...1
28.05.OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-802-
12.05.OCUMENSION-B (01477): GRANTS OF OPTIONS AND AWARDS-
28.04.OCUMENSION-B (01477): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS1
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1